-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The level of medicine machines is related to the quality and safety of medicin.
In recent years, with the accelerated transformation and upgrading of the domestic pharmaceutical industry and the rapid development of biological drugs, under the background of the continuous expansion of the demand for pharmaceutical equipment and the continuous improvement of requirements, more and more pharmaceutical machine companies have begun to aim at the vast domestic pharmaceutical equipme.
The blue ocean of the market, and the determination to enter or increase the layout of biopharmaceutical equipment, precision manufacturing and other fiel.
According to the author's understanding, since this year, many pharmaceutical machine companies have been in full swing in the establishment of subsidiaries and the construction of industrialization projec.
Taking Chutian Technology as an example, it announced on August 2 that the company intends to jointly fund the establishment of a company in Ningxiang City, Changsha, Hunan Province to provide medical equipment, medical equipment, mechanical engineering and other related industries with a team of experts in the precision manufacturing indust.
It is a company whose main business is precision manufacturing and mol.
The name of the joint venture company is Chutian Changxing Precision Manufacturing (Changsha) .
, L.
(hereinafter referred to as "Chutian Changxing"), with a registered capital of 50 million yu.
After the establishment of the joint venture, the company subscribed and contributed 25 million yuan, accounting for 51% of its equity, and was the company's holding subsidia.
It is understood that on February 7, the construction of the Chutian Technology 10-billion-capacity intelligent manufacturing base project started in Ningxiang City, and before that, Chutian Technology has completed the fourth phase of construction in 202 The fifth phase of the project mainly builds R&D, manufacturing and management units such as the central workshop, the intelligent after-package workshop, and the biological tank group worksh.
The project is expected to complete the construction task in the first half of 202 The industry believes that soon after the opening of 2022, the company has invested in the construction of the fifth phase of the project, which shows its determination to increase the size of the mark.
In addition to Chutian Technology, Tofflon also disclosed on February 28 that the company plans to raise no more than 2 billion yuan for a number of biomedical equipment industrialization projec.
Before that, Tofflon Intelligent Equipment Manufacturing (Jiangsu) .
, L.
, a wholly-owned subsidiary of Tofflon, has also obtained the "Jiangsu Province Investment Project Recording Certificate" issued by the Administrative Examination and Approval Bureau of Dongtai City, Jiangsu Provin.
According to public information, the project plans to use 990 million yuan of raised funds
The project overview shows that the industrialization base project is constructed by the company in combination with the evolution trend of domestic and foreign pharmaceutical processes and the upgrading needs of downstream custome.
Product capaci.
In addition, it was reported earlier that the R&D and industrialization project of disposable equipment/consumables with a total investment of 200 million yuan for Bailinke Pharmaceutical Machinery has been completed and put into operation at present, and the average annual R&D investment will be reach more than 1
In addition, Phase V expansion products and service workshops are scheduled to be put into production in the first quarter of 202 It is reported that the company's self-developed products have broken through the "stuck neck" technolo.
As a technology manufacturing enterprise, Bailinke Pharmaceutical Equipment regards technological innovation and product innovation as its lifeli.
After all its disposable consumables production bases are put into operation, the company will continue to integrate the achievements of university-industry-university-research cooperation, and strive to achieve continuous supply of localized products in the field of biopharmaceutical equipment and consumabl.
From the above point of view, in the current changing pharmaceutical environment, the development goal of domestic pharmaceutical machine enterprises is not simply to pursue profit, but to pursue diversification of development, and is committed to continuously expanding business and creating new projects to find industry More new growth poin.
Among them, it includes both products, services and internationalizati.
The industry expects that under this background, the domestic pharmaceutical equipment industry structure will continue to be optimized, and the market mechanism will continue to improve, thereby promoting the accelerated development of China's pharmaceutical equipment industry in the direction of high quali.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
In recent years, with the accelerated transformation and upgrading of the domestic pharmaceutical industry and the rapid development of biological drugs, under the background of the continuous expansion of the demand for pharmaceutical equipment and the continuous improvement of requirements, more and more pharmaceutical machine companies have begun to aim at the vast domestic pharmaceutical equipme.
The blue ocean of the market, and the determination to enter or increase the layout of biopharmaceutical equipment, precision manufacturing and other fiel.
According to the author's understanding, since this year, many pharmaceutical machine companies have been in full swing in the establishment of subsidiaries and the construction of industrialization projec.
Taking Chutian Technology as an example, it announced on August 2 that the company intends to jointly fund the establishment of a company in Ningxiang City, Changsha, Hunan Province to provide medical equipment, medical equipment, mechanical engineering and other related industries with a team of experts in the precision manufacturing indust.
It is a company whose main business is precision manufacturing and mol.
The name of the joint venture company is Chutian Changxing Precision Manufacturing (Changsha) .
, L.
(hereinafter referred to as "Chutian Changxing"), with a registered capital of 50 million yu.
After the establishment of the joint venture, the company subscribed and contributed 25 million yuan, accounting for 51% of its equity, and was the company's holding subsidia.
It is understood that on February 7, the construction of the Chutian Technology 10-billion-capacity intelligent manufacturing base project started in Ningxiang City, and before that, Chutian Technology has completed the fourth phase of construction in 202 The fifth phase of the project mainly builds R&D, manufacturing and management units such as the central workshop, the intelligent after-package workshop, and the biological tank group worksh.
The project is expected to complete the construction task in the first half of 202 The industry believes that soon after the opening of 2022, the company has invested in the construction of the fifth phase of the project, which shows its determination to increase the size of the mark.
In addition to Chutian Technology, Tofflon also disclosed on February 28 that the company plans to raise no more than 2 billion yuan for a number of biomedical equipment industrialization projec.
Before that, Tofflon Intelligent Equipment Manufacturing (Jiangsu) .
, L.
, a wholly-owned subsidiary of Tofflon, has also obtained the "Jiangsu Province Investment Project Recording Certificate" issued by the Administrative Examination and Approval Bureau of Dongtai City, Jiangsu Provin.
According to public information, the project plans to use 990 million yuan of raised funds
The project overview shows that the industrialization base project is constructed by the company in combination with the evolution trend of domestic and foreign pharmaceutical processes and the upgrading needs of downstream custome.
Product capaci.
In addition, it was reported earlier that the R&D and industrialization project of disposable equipment/consumables with a total investment of 200 million yuan for Bailinke Pharmaceutical Machinery has been completed and put into operation at present, and the average annual R&D investment will be reach more than 1
In addition, Phase V expansion products and service workshops are scheduled to be put into production in the first quarter of 202 It is reported that the company's self-developed products have broken through the "stuck neck" technolo.
As a technology manufacturing enterprise, Bailinke Pharmaceutical Equipment regards technological innovation and product innovation as its lifeli.
After all its disposable consumables production bases are put into operation, the company will continue to integrate the achievements of university-industry-university-research cooperation, and strive to achieve continuous supply of localized products in the field of biopharmaceutical equipment and consumabl.
From the above point of view, in the current changing pharmaceutical environment, the development goal of domestic pharmaceutical machine enterprises is not simply to pursue profit, but to pursue diversification of development, and is committed to continuously expanding business and creating new projects to find industry More new growth poin.
Among them, it includes both products, services and internationalizati.
The industry expects that under this background, the domestic pharmaceutical equipment industry structure will continue to be optimized, and the market mechanism will continue to improve, thereby promoting the accelerated development of China's pharmaceutical equipment industry in the direction of high quali.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
